• Clinical Trials - Lung cancer

    Study Objective Contact
    A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications. [LCID Study Number: 2013-051] This is a Phase 1, open-label, trial of (Drug) MSB0010718C [antibody targeting anti PD-L1] in subjects with Metastatic Breast Cancer and Metastatic Non Small Cell Lung Cancer. Principal Investigator(s):
    Corrine Zarwan, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Julie Roache.
    Circulating Tumor Cells in Patients with Primary Carcinoma of the Lung and Patients who are Candidates for Pulmonary Metastasectomy for Metastatic Colorectal, Breast, and Prostate Cancer [LCID Study Number: 2011-076] Why is this study being done? To determine if tumor cells can be isolated and treated from peripheral blood and blood from the part of lung that is being removed for the treatment of the tumor. Principal Investigator(s):
    Christina Williamson, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Deborah J. Gannon,
    Frances A. Babcock.
    Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network [LCID Study Number: 2011-026] To collect, process, store, and distribute tumor-related and normal biospecimens from advanced stage lung cancer patients in support of ALCMI-approved research projects. To maintain a centralized, computerized database of all specimens with uniform and complete demographic, pathologic, and clinical information. To facilitate integration of molecular assays and other laboratory studies with demographic data and clinical outcomes. To obtain funding from National Institutes of Health based on the use of the biorepository to enable or discovery of novel genes and proteins that are being investigated by the academic contributors. Principal Investigator(s):
    Paul J. Hesketh, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Amanda M. Pietras.
    LCCC/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening: Reducing Dependence on Tobacco [LCID Study Number: 2013-089] This research study is looking at helping smokers and recent smokers quit and stay smoke free when they undergo lung cancer screening. Together with Low Dose CT Lung Cancer Screening, Lahey is offering the opportunity to participate in 2 research studies. The first study is looking at taking cells from your nose with a swab to see if these cells are different in people with lung cancer. The second study is a research study with our partners at Georgetown University to see if providing smokers and recently quit smokers (quit within the last year) extra help on how to quit and stay smoke free, at the same time they are undergoing lung cancer screening, will make it more likely they will be successful. Principal Investigator(s):
    Andrea B. McKee, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Andrea B. Kitts,
    Shawn M. Regis, PhD.
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.
    RTOG 1306: A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non Small Cell Lung Cancer (NSCLC) [LCID Study Number: 2013-068] This randomized phase II trial studies how well giving erlotinib hydrochloride or crizotinib and chemoradiation therapy works in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, etoposide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving erlotinib hydrochloride is more effective than crizotinib with chemoradiation therapy in treating patients with non-small cell lung cancer. Principal Investigator(s):
    Jacob M. Sands, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Eileen T. Cirino, MS,
    Julie Roache.
    S0819: A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel Or Carboplatin/Paclitaxel/Bevacizumab With Or Without Concurrent Cetuximab In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [LCID Study Number: 2010-046] The purpose of this study is compare the effects, good and/or bad, of the addition of cetuximab to the common treatment of carboplatin, paclitaxel and bevacizumab to the same drugs without cetuximab on you and your lung cancer to find out which is better. Principal Investigator(s):
    Paul J. Hesketh, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Julie Roache.
    TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance Mutation [LCID Study Number: 2014-034] The purpose of this study is to evaluate the safety and anti-tumor effect of CO-1686, an investigational oral medication, to participants whose tumors did not respond or stopped responding to treatment. with their first. The trial is open-ended, which means patients will continue to take CO-1686 until the study doctor determines it is no longer beneficial for them. Principal Investigator(s):
    Paul J. Hesketh, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Julie Roache.